Get the Stockscreener App
306.31
1.43%
4.31
After Hours:
306.24
-0.07
-0.02%
Charles River Laboratories International Inc stock is traded at $306.31, with a volume of 793.60K.
It is up +1.43% in the last 24 hours and up +12.25% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$302.00
Open:
$301.81
24h Volume:
793.60K
Relative Volume:
0.81
Market Cap:
$14.62B
Revenue:
$4.03B
Net Income/Loss:
$-182.84M
P/E Ratio:
-81.46
EPS:
-3.7603
Net Cash Flow:
$391.29M
1W Performance:
+2.79%
1M Performance:
+12.25%
6M Performance:
+69.64%
1Y Performance:
+79.42%
1-Day Range:
$295.40
$309.48
1-Week Range:
$294.60
$310.53
52-Week Range:
$146.19
$333.30
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
306.31 | 14.62B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
696.57 | 257.55B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
231.55 | 162.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.36 | 58.29B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.53 | 49.49B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
271.22 | 44.64B | 16.63B | 1.39B | 2.12B | 8.0674 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-26 | Resumed | UBS | Buy |
| Aug-06-26 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-20-26 | Downgrade | CLSA | Outperform → Hold |
| Jun-17-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-29-26 | Upgrade | CLSA | Hold → Outperform |
| Apr-14-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-17-25 | Upgrade | Argus | Hold → Buy |
| Nov-06-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-06-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-02-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $324.87, Implies 8% Upside - TradingView
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera - GlobeNewswire Inc.
Form 144 CHARLES RIVER LABORATORIES INTERNATIONAL For: 12 October By Investing.com - Investing.com Canada
Is Charles River Laboratories International (CRL) Fairly Valued After The Apollo Orchestrate Launch? - Simply Wall Street
Q2 2026 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call - BioSpace
Charles River and Autolomous launch Apollo Orchestrate for digital laboratory execution - BioSpectrum Asia
Form 4 Charles River Laboratories International, Inc For: 7 October By Investing.com - Investing.com Nigeria
Charles River Labs CEO Shannon Parisotto sells $302k in stock - Investing.com
Form 4 Charles River Laboratories International, Inc For: 7 October By Investing.com - Investing.com India
Charles River Labs CEO Shannon Parisotto sells $302k in stock - Investing.com UK
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
PGNY or CRL: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Yahoo! Finance Canada
Charles River Gains 75.8% in a Year: What's Driving the Rally? - TradingView
Could Apollo Orchestrate Launch Shift Charles River Labs Stock Narrative - Simply Wall Street
Could Apollo Orchestrate Launch Shift Charles River Labs Stock Narrative - Simply Wall Street
Global Animal Model Market Report 2026-2034 by Animal Type, Technology, Application, End User, and Region | CRISPR and Drug Discovery Drive Growth to USD 3.31 Billion - GlobeNewswire Inc.
Charles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo Platform - marketscreener.com
Is It Prudent to Add Teleflex Stock to Your Portfolio Now? - Zacks Investment Research
Charles River and Autolomous Partner to Transform Laboratory Execution Systems - Business Wire
Charles River Laboratories International Inc. Research & Ratings | CRL - Barron's
A Look at Charles River Laboratories International Inc (CRL) Aft - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
An officer proposes selling 981 option-acquired shares of Charles River (CRL). - Stock Titan
Charles River Laboratories International Inc Stock (CRL) Closed Up by 7.09% on Oct 5: Key Drivers Unveiled - TradingKey
Charles River Laboratories International Jumps 5.6% in Broad Rally - AlphaStreet
Charles River Laboratories Gains as Investor Day Targets and Analyst Support Lift Sentiment - Quiver Quantitative
Charles River Laboratories stock hits 52-week high at 303.33 USD - Investing.com
Cell and Gene Therapy Biomanufacturing MarketSize, Share, and Forecast, 2026-2031 | Automation, Viral Vectors, and CDMO Expansion Drive 11.7% CAGR to $8.7 Billion - GlobeNewswire Inc.
What You Can Learn From Charles River Holders Who Are Up 64% - Simply Wall Street
What You Can Learn From Charles River Holders Who Are Up 64% - Simply Wall Street
Q2 2026 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus
Charles River Laboratories (CRL) EVP & CFO Glenn Coleman Buys 10 Shares - GuruFocus
Is Charles River Laboratories International (CRL) Fairly Valued Or Is More Upside Left? - Simply Wall Street
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Charles River Laboratories International, Inc. (CRL) latest stock news and headlines - sg.finance.yahoo.com
Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases - Yahoo Finance
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175 - Moomoo
Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today - Benzinga
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research
UBS resumes Charles River Labs stock coverage with buy rating - Investing.com
UBS Initiates Buy on Charles River Laboratories (CRL) Amid Positive CRO Sector Outlook - gurufocus.com
Charles River Laboratories stock pre-market as Cooke & Bieler cites demand stabilization - AD HOC NEWS
Computer-Aided Drug DiscoveryGlobal Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secur - Supply Chain Digital
Return on invested capital % of Charles River Laboratories International, Inc. – HAN:RV6 - TradingView
Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery - finance.yahoo.com
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Charles River Laboratories International Inc Stock (CRL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Oct 05 '26 |
Sale |
308.44 |
981 |
302,580 |
4,807 |
| Parisotto Shannon M | Officer |
Oct 05 '26 |
Proposed Sale |
314.56 |
981 |
308,580 |
0 |
| Coleman Glenn | EVP & Chief Financial Officer |
Sep 30 '26 |
Buy |
297.43 |
10 |
2,974 |
27,762 |
| FOSTER JAMES C | Director |
Aug 25 '26 |
Option Exercise |
199.42 |
33,561 |
6,692,845 |
65,157 |
| FOSTER JAMES C | Director |
Aug 25 '26 |
Proposed Sale |
299.93 |
33,561 |
10,065,951 |
0 |
| FOSTER JAMES C | Director |
Aug 25 '26 |
Sale |
300.00 |
33,561 |
10,068,300 |
31,596 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Aug 19 '26 |
Option Exercise |
194.12 |
2,039 |
395,811 |
6,846 |
| Parisotto Shannon M | Officer |
Aug 19 '26 |
Proposed Sale |
294.12 |
2,039 |
599,711 |
0 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Aug 19 '26 |
Sale |
294.12 |
2,039 |
599,711 |
4,807 |
| Andrews Nancy C | Director |
Aug 18 '26 |
Sale |
285.24 |
573 |
163,443 |
1,438 |
3.72%
3.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):